LG-2527
From Wikipedia, the free encyclopedia
Clinical data | |
---|---|
Drug class | Progestin; Progestogen |
LG-2527 is a nonsteroidal progestin which was under development by Ligand Pharmaceuticals and Wyeth for the treatment of menopausal symptoms and breast cancer but was never marketed.[1] It reached the preclinical stage of development prior to the discontinuation of its development in early 2001.[1]
References[]
- ^ a b "LG 2527 - AdisInsight". adisinsight.springer.com.
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by . |
- v
- t
Retrieved from ""
Categories:
- Abandoned drugs
- Drugs with undisclosed chemical structures
- Hormonal antineoplastic drugs
- Progestogens
- Genito-urinary system drug stubs
Hidden categories:
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- All stub articles